Literature DB >> 20505028

Imaging in drug development: will it deliver on the promise of personalised medicine?

A Dzik-Jurasz1.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20505028      PMCID： PMC3473602          DOI： 10.1259/bjr/65491666

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


× No keyword cloud information.
  7 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

2.  Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?

Authors:  Jerry M Collins
Journal:  J Clin Oncol       Date:  2005-07-18       Impact factor: 44.544

3.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Authors:  Lalitha K Shankar; John M Hoffman; Steve Bacharach; Michael M Graham; Joel Karp; Adriaan A Lammertsma; Steven Larson; David A Mankoff; Barry A Siegel; Annick Van den Abbeele; Jeffrey Yap; Daniel Sullivan
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

Review 4.  Economics of new oncology drug development.

Authors:  Joseph A DiMasi; Henry G Grabowski
Journal:  J Clin Oncol       Date:  2007-01-10       Impact factor: 44.544

5.  Are targeted contrast agents realistically going to reach the clinic? Recent regulatory experience with targeted MRI contrast agents.

Authors:  A Dzik-Jurasz
Journal:  Br J Radiol       Date:  2006-08-31       Impact factor: 3.039

6.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

7.  The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Authors:  M O Leach; K M Brindle; J L Evelhoch; J R Griffiths; M R Horsman; A Jackson; G C Jayson; I R Judson; M V Knopp; R J Maxwell; D McIntyre; A R Padhani; P Price; R Rathbone; G J Rustin; P S Tofts; G M Tozer; W Vennart; J C Waterton; S R Williams; P Workman
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.